K
Kailera Therapeutics
A clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions
About Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on the rapidly growing market for obesity and related metabolic conditions. The company launched in October 2024 with a substantial $400 million Series A financing, co-led by prominent investors Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with Lyra Capital also participating. This significant initial funding allows Kailera to bypass early research stages and advance a portfolio of clinical-stage assets. The company's business model centers on acquiring and developing promising drug candidates. In May 2024, Kailera secured exclusive rights to develop and commercialize a portfolio of four metabolic disease assets outside of Greater China from Jiangsu Hengrui Pharmaceuticals.
Read full description
The leadership team is composed of seasoned biotech executives. CEO Ron Renaud has a notable history of leading companies to successful acquisitions, including Cerevel Therapeutics (acquired by AbbVie), Translate Bio (acquired by Sanofi), and Idenix Pharmaceuticals (acquired by Merck & Co.). The board is chaired by John F. Milligan, the former President and CEO of Gilead Sciences, who was instrumental in its growth into a global biopharmaceutical leader.
Kailera's product pipeline is diverse, featuring both injectable and oral therapies targeting chronic weight management. Its most advanced program is KAI-9531, an injectable dual agonist targeting GLP-1 and GIP receptors. This candidate has already produced compelling results in Phase 2 trials for obesity and type 2 diabetes conducted in China. The pipeline also includes KAI-7535, an oral small molecule GLP-1 receptor agonist; an oral tablet formulation of KAI-9531; and KAI-4729, an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors. This multi-faceted approach, with various mechanisms and delivery routes, is designed to address complex patient needs in a market currently dominated by major pharmaceutical players.
At a glance
- Founded
- 2024
- Headquarters
- Waltham, United States
- Listing
- IPO 2026
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Kailera Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Bain Capital Life Sciences
Atlas Venture
RTW Investments- LCLyra Capital
- BEBain Capital Private Equity
CPP Investments
T. Rowe Price
Perseverance Capital Management
Qatar Investment Authority- SCSirona Capital
Surveyor Capital
Invus
Royalty Pharma
Janus Henderson Investors
Series B and later10 investors entered at this stage
- Qatar Investment Authority
- BEBain Capital Private Equity
- CPP Investments
- T. Rowe Price
- PMPerseverance Capital Management
- INInvus
- SCSirona Capital
- SCSurveyor Capital
- RPRoyalty Pharma
- Janus Henderson Investors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kailera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kailera Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.